Cancer Research, Statistics, and Treatment最新文献

{"title":"Of ecstasy and agony","authors":"R. Pradhan","doi":"10.4103/crst.crst_15_23","DOIUrl":"https://doi.org/10.4103/crst.crst_15_23","url":null,"abstract":"","PeriodicalId":9427,"journal":{"name":"Cancer Research, Statistics, and Treatment","volume":"3 1","pages":"88 - 90"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86806319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Deep learning for prediction of radiation-induced oral mucositis: Need for longitudinal studies","authors":"Amit Gupta, Krithika Rangarajan","doi":"10.4103/crst.crst_263_23","DOIUrl":"https://doi.org/10.4103/crst.crst_263_23","url":null,"abstract":"We read with great interest the original study, “Artificial intelligence-based prediction of oral mucositis in patients with head-and-neck cancer: A prospective observational study utilizing a thermographic approach” by Thukral et al., recently published in the Cancer Research, Statistics, and Treatment journal.[1] In this cross-sectional study, the authors described a convolutional neural network-based deep learning algorithm for classifying thermographic images of patients with head-and-neck cancer undergoing radiotherapy according to the absence or presence of early oral mucositis changes. The authors demonstrated a high accuracy (82.05%) of the proposed model for the classification of the testing dataset. We have a few comments to make regarding this study. Radiation-induced oral mucositis is a frequent complication of radiotherapy in patients with head-and-neck cancers, which can vary greatly in severity from mild erythema and pain to extremely debilitating oral ulcers precluding any per-oral alimentation.[2] The management is mainly symptomatic and may necessitate invasive means of alimentation along with interruption of radiation therapy.[3] Although the exact pathogenesis of radiation-induced oral mucositis is still poorly understood, good oral health, adequate nutritional status, and advanced modulated radiotherapy regimens have been shown to have a prophylactic effect.[4] In particular, alimentation via percutaneous endoscopic gastrostomy (PEG) early in the course of radiotherapy has been shown to prevent higher grades of radiation-induced oral mucositis and consequent interruption of therapy.[4] In this regard, the true predictive application of artificial intelligence lies in identifying those patients with head-and-neck cancer who are more likely to develop higher grades of radiation-induced oral mucositis with continued radiotherapy treatment and thus are candidates for more aggressive prophylactic measures like PEG or de-intensification of therapy. Although the study by Thukral et al.[1] showed an excellent diagnostic performance of the deep learning algorithm for the detection of early oral mucositis changes on thermography images, there were some important drawbacks. Being a cross-sectional study, the subsequent development of higher grades of radiation-induced oral mucositis with higher cumulative radiation doses could not be studied. The authors did not consider the duration, regimen, planning, and dose of radiotherapy following which the patients were evaluated. The relatively small sample size made the deep learning algorithm prone to overfitting. It is important to avoid using different images from the same patient in both the training and testing datasets—the study methodology did not mention this. The validation of the deep learning algorithm should have been done by testing on patient data collected in the natural course of their disease rather than collated enriched data. Finally, we would like to recommend that the rese","PeriodicalId":9427,"journal":{"name":"Cancer Research, Statistics, and Treatment","volume":"3 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135784765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Etiology, clinical profile, and treatment pattern of hepatocellular carcinoma at a tertiary care center in North India: A retrospective observational study","authors":"Shaheena Parveen, Syed Nisar Ahmad, Abdul Wahid Mir, Altaf Hussain Shah, Tariq Abdullah Mir, Zubaida Rasool, Mohamad Younis Bhat, Nazir Ahmad Dar, Gull Mohammad Bhat","doi":"10.4103/crst.crst_37_23","DOIUrl":"https://doi.org/10.4103/crst.crst_37_23","url":null,"abstract":"ABSTRACT Export Background: The prognosis of patients with hepatocellular carcinoma (HCC) is poor due to its non-specific presentation, underlying liver disease, and advanced stage at presentation. There are limited HCC data from India, and no major studies are available from North India. Objectives: To study the epidemiology, etiological factors, clinical profiles, and treatment patterns of patients with HCC at our center. Materials and Methods: This was a retrospective analysis of prospectively collected data of patients with HCC from January 2016 to December 2020, conducted in the Department of Medical Oncology and Gastroenterology at the Sher-i-Kashmir Institute of Medical Sciences (SKIMS), a tertiary center in North India. Patient data and treatment details were collected and analyzed. Results: We enrolled 127 patients in the study. Males constituted the majority (91; 71.7%), with a mean age of 58 ± 12 years. The majority (100; 78%) of patients had cirrhosis; the common etiological factors included hepatitis B virus infection (30; 23.6%), non-alcoholic steatohepatitis (29; 22.8%), and hepatitis C virus infection (22; 17.3%). Although etiology was unknown in 45 (35.4%) patients, around one-third (36.4%) had diabetes mellitus. Most (91; 71.7%) patients had liver-limited disease and the majority (53; 41.7%) presented with Barcelona Clinic Liver Cancer (BCLC) stage C disease, followed by BCLC A (33; 26%), BCLC B (25; 19.7%), and BCLC D (16; 12.6%). Portal vein thrombosis was noted in 40 (32.3%) patients. Liver-directed therapies, including surgery, ablation, and trans-arterial chemoembolization, were received by 17 (13.4%) patients. The most commonly used systemic treatments were sorafenib (32; 25.2%) and lenvatinib (7; 5.5%), but a substantial number of patients (56/127; 44.1%) either did not adhere to, refused therapy or were given best supportive care. Conclusion: The majority of patients with HCC at our center are males and present at a mean age of 58 years. Hepatitis B virus is the most frequent etiological agent. Patients with HCC present with advanced stage disease and are often not considered suitable for curative intent treatment. Sorafenib is the most commonly administered systemic treatment; however, just under half the patients (44.1%) are either unfit for or refuse treatment.","PeriodicalId":9427,"journal":{"name":"Cancer Research, Statistics, and Treatment","volume":"17 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135784770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A practical and practicable framework for implementing cardiac-sparing radiotherapy techniques in breast cancer","authors":"Kundan S. Chufal, Irfan Ahmad, Alexis A. Miller, Atul Tyagi, Preetha Umesh, Rahul L. Chowdhary, Muhammed I. Sharief, Munish Gairola","doi":"10.4103/crst.crst_33_23","DOIUrl":"https://doi.org/10.4103/crst.crst_33_23","url":null,"abstract":"Advances in the treatment of breast cancer have resulted in a consistent trend toward improved outcomes worldwide. From the perspective of low- and middle-income countries (LMIC) these improved outcomes offer hope despite an increase in the incidence of breast cancer.[1] However, a substantial proportion of women treated with adjuvant radiotherapy in LMICs are at risk of developing late radiation-induced cardiac morbidity owing to the lack of appropriate radiotherapy infrastructure.[2] This risk is reflected in a higher heart mean dose (Dmean) in Asian LMICs over the last two decades and compounded by an overall higher proportion of the global burden of cardiovascular diseases.[3,4] After accounting for reporting bias, the actual heart Dmean is likely higher in routine community practice and, disconcertingly, remains unknown in those treated on Cobalt-60 (Co60) machines. Measures can be instituted to reduce the heart Dmean with increasing levels of available resources in LMICs, namely: (a) adopting hypofractionated treatment schedules; (b) avoiding internal mammary nodal irradiation in early breast cancer (EBC) when using Co60 machines; (c) excluding ribs and intercostal muscles during target delineation; (d) preferring forward-planned approaches (with breath control), and; (e) reserving inverse-planned approaches for patients with unfavorable anatomy (and/or unsuitable for breath control).[5-7] In a recent survey of more than 2000 radiation oncologists worldwide, the lowest adoption of hypofractionated treatment schedules in breast cancer was in LMICs.[8] The advantage of shorter fractionation schedules in resource constrained LMICs is obvious, yet a third of the respondents voiced concerns regarding late toxicity. The results of hypofractionated trials (most allowed Co60 treatment) should allay this concern. The anticipated effect of hypofractionated radiotherapy on cardiac function is lower than conventional fractionation, owing to a reduced heart Dmean after Equivalent Dose in 2 Gy (EQD2) conversion.[9] Dosimetric studies have demonstrated that unless the α/β ratio of the heart is lower than 1.5, almost all hypofractionated schedules have a lower EQD2 Dmean compared to conventional fractionation.[9] Acknowledging the limitations of dosimetric modeling in predicting complex cardiac events, we endorse prospective data collection on cardiac outcomes. Yet the current generation of trials in radiation oncology with cardiac-specific outcomes are designed to assess the efficacy of conventionally fractionated Proton Beam Therapy (PBT), a technology that can potentially reduce heart Dmean to near-zero, but in LMICs, this will benefit only those with financial resources.[10] Treating internal mammary nodes (IMC) to replicate the positive results of elective regional nodal irradiation (RNI) trials with Co60 machines should be reconsidered. Since a linear relationship exists between heart Dmean and the risk of major cardiac events at 10 years, the Co60 t","PeriodicalId":9427,"journal":{"name":"Cancer Research, Statistics, and Treatment","volume":"25 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135700462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Authors’ reply to Reddy","authors":"Anupama Radhakrishnan, Pritha Roy, Krishnangshu B. Choudhury, Ritam Joarder, Partha Dasgupta","doi":"10.4103/crst.crst_274_23","DOIUrl":"https://doi.org/10.4103/crst.crst_274_23","url":null,"abstract":"We sincerely appreciate the thoughtful comments made by Reddy[1] in his correspondence regarding our study, “The impact of pathological complete response on survival in patients with breast cancer and occurrence in different intrinsic subtypes: A retrospective observational study.”[2] We are pleased to address the points raised in the letter. Ghosh and Ganguly[3] aptly emphasized the multifaceted nature of the pathological complete response (pCR) as a surrogate marker for survival outcomes in neoadjuvant clinical trials. We concur that pCR may not serve as an absolute predictor of long-term survival, as evidenced by the contrasting findings in previous studies,[4] including those highlighted by Conforti et al.[5] and Cortazar et al.[6] Our study sought to contribute to this ongoing discourse by evaluating the correlation of pCR with outcomes within the context of different intrinsic subtypes of breast cancer while evaluating our own practice at the same time. Ghosh and Ganguly[3] pointed out the potential influence of differing neoadjuvant chemotherapy regimens on the attainment of pCR. As rightly pointed out by Reddy,[1] including patients who received more than or at least six cycles of neoadjuvant chemotherapy would have been more prudent, and we intend to re-look at our data from this new perspective. This could have been the reason behind the modest pCR rate of 16.7% achieved in our study.[2] Additionally, the absence of data regarding adjuvant treatment and subsequent lines of therapy is noted, and this could certainly have played a role in influencing survival outcomes. However, we would like to point out that the compliance of our patients to anti-HER2 therapy in the adjuvant setting was better than that observed in the neoadjuvant setting. We are gratified by the inclusion of insights from the CREATE-X[7] and KATHERINE trials,[8] which underscore the evolving landscape of pCR’s predictive potential. The results from these trials support the notion that pCR can guide treatment modifications and lead to improved outcomes. Results from these trials are now being incorporated regularly in clinical practice; this study was an eye-opener for us, and it will hopefully motivate others as well. In conclusion, we concur with Ghosh and Ganguly’s[3] assertion that while the role of pCR as a survival marker in clinical trials remains debated, it does hold significant prognostic value for individuals.[9] We extend our gratitude to them for enriching the discourse surrounding our study and the broader understanding of the implications of achieving pCR and also to Reddy for his insights.[1] Further data from real-world settings will undoubtedly shed more light on the intricate interplay between pCR, treatment strategies, and patient outcomes. Financial support and sponsorship Nil. Conflicts of interest There are no conflicts of interest.","PeriodicalId":9427,"journal":{"name":"Cancer Research, Statistics, and Treatment","volume":"105 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135700834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genetic counseling for hereditary cancers: Not everybody’s cup of tea!","authors":"Rekha Gupta, Satyajeet Soni, Hemant Malhotra","doi":"10.4103/crst.crst_271_23","DOIUrl":"https://doi.org/10.4103/crst.crst_271_23","url":null,"abstract":"We read with deep interest the review article published in the previous issue of Cancer Research Statistics and Treatment authored by Ulhaq et al.[1] We feel that this manuscript is of utmost importance for practicing oncologists and the journal needs to be congratulated for selecting this for publication to highlight this issue. After more than three decades of practicing oncology in the country, the senior writer of this letter is acutely aware of the lack of knowledge among treating clinicians and the extreme dearth of trained genetic counselors. Hereditary cancer contributes 5–10% of the overall cancer incidence. Early diagnosis and treatment are the most successful tools in cancer management for a higher survival rate. This principle can be applied to hereditary cancer families by identifying high-risk individuals and putting them on surveillance. Genetic counseling is the first step in this process. Pivotal steps have been discussed in the article.[1] Developing genetic counseling units with specialization in oncology is an important step towards generating awareness about hereditary cancer syndromes. As multiple family members are at risk of developing cancer, multiple lives can be saved by providing surveillance and prevention to such families. Counseling and offering genetic testing based on the next-generation sequencing (NGS) and multiplex ligation-dependent probe amplification (MLPA) techniques is at the heart of this concept of prevention, early diagnosis, and treatment. A few important issues were not highlighted in this article.[1] One important issue in the Indian scenario is pre-symptomatic carrier detection in a young person and marriage-related issues,[2] and the reproductive implications of this diagnosis. Such individuals carry a lifetime risk of cancer, and their offspring will harbor the mutation in 50% of cases. Genetic counseling must be offered to such reproductive couples. Preimplantation genetic diagnosis (PGD) can be offered to couples who are conceiving through in vitro fertilization (IVF). The second important issue is the psychological stress of receiving a pre-symptomatic diagnosis. These newly diagnosed pre-symptomatic carriers are young individuals who are on the verge of their careers and starting their reproductive lives. We need a team of support groups, counselors, and psychologists to take care of the pre-symptomatic diagnosis hurdles amidst job security, insurance policy, etc. The authors, even though they claim to have written an India-specific article, have missed out on at least three major publications in the field from India which significantly add to the knowledge on the subject.[3-5] The cost of testing and surveillance also needs to be considered by the individual patient/person. Now, with a large industrial house with deep pockets, entering the field of genetic testing and promising comprehensive genetic profiling at less than `15,000, a whole set of new and unknown issues are bound to arise, and ","PeriodicalId":9427,"journal":{"name":"Cancer Research, Statistics, and Treatment","volume":"278 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135700841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intraocular tumors and biopsy (buy-a-see)","authors":"Sunny Chi Lik Au","doi":"10.4103/crst.crst_103_23","DOIUrl":"https://doi.org/10.4103/crst.crst_103_23","url":null,"abstract":"Cancers and tumors are a challenge to face, a foe to fight; Oncologists and their teams, a path to trace, a hope in sight. Within the eye, a tumor grows; A silent threat that nobody knows. The news, sometimes, is hard to take; The doctor often wonders what steps to make. A biopsy, the doctor takes a deep breath, then says with care; For the patient, to balance the bills of death, it’s hard to bear. The biopsy shows something we cannot ignore; And we know we must “buy-a-see” for something more. Denial and anger, at first, do show; Acceptance and appreciation, with time, do grow. Take the oncology journey, one step at a time; We know that we have the strength to climb. Oncology as a team, with knowledge and care; Gives patients the strength, the flight to bear. The road is long, and the journey is tough; The team works together to show they are enough. Financial support and sponsorship Nil. Conflicts of interest There are no conflicts of interest.","PeriodicalId":9427,"journal":{"name":"Cancer Research, Statistics, and Treatment","volume":"87 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135701146","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Authors' reply to Thavarool et al.","authors":"Prachi Bhatia, Madhura R. Sharma, G. Singh, S. Gurav","doi":"10.4103/crst.crst_85_23","DOIUrl":"https://doi.org/10.4103/crst.crst_85_23","url":null,"abstract":"","PeriodicalId":9427,"journal":{"name":"Cancer Research, Statistics, and Treatment","volume":"8 1","pages":"138 - 139"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87320669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Extramedullary spinal tumors: Cross-sectional study of the demographic characteristics and treatment outcomes of surgically treated patients from Isfahan (Iran)","authors":"Mehdi Mahmoodkhani, Mehdi Shafiei, M. Sharifi, A. Naeimi, D. Tehrani","doi":"10.4103/crst.crst_237_22","DOIUrl":"https://doi.org/10.4103/crst.crst_237_22","url":null,"abstract":"Background: Extramedullary tumors account for a small percentage of all the tumors of the central nervous system and spine. Objectives: We aimed to determine the demographic characteristics and outcomes of treatment of patients with surgically resected extramedullary spinal tumors who visited medical centers in Isfahan, Iran. Materials and Methods: This descriptive study was conducted in Alzahra and Kashani medical centers in Isfahan, Iran, between 2013 and 2021. Patients with extramedullary spinal tumors who underwent surgery were included. Data collected included the pain score as measured on the visual analog scale (VAS) for pain severity, and the patients' neurological and functional status before and after treatment, as assessed on the McCormick scale. Results: We enrolled 94 patients in the study. The most common extramedullary spinal tumors were nerve sheath tumors in 32 (34.1%) patients, meningiomas in 27 (28.8%), and metastases in 22 (23.4%). The median follow-up was 3.60 ± 2.33 years. Pain was reported by 89 (94.7%) patients, which remained unresolved in 11 (13.5%) even after treatment; 18 (19.1%) patients died, among whom 8 (44.4%) had metastatic disease. As per the McCormick scale, 35 of 62 patients (46.1%) had a complete recovery following the various treatments including surgery, chemotherapy, and radiotherapy in the follow-up. Conclusion: There is an analogous distribution of extramedullary spinal tumors in Iranian patients compared to global data. In Iran, nerve sheath tumors and meningiomas are the most common extramedullary tumor types, and pain is the most common initial manifestation of these tumors. Surgical intervention in patients with extramedullary tumors usually leads to complete recovery based on the McCormick scale and reduction of pain symptoms as per the pain–VAS.","PeriodicalId":9427,"journal":{"name":"Cancer Research, Statistics, and Treatment","volume":"30 1","pages":"26 - 31"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86916774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cabozantinib: A narrative drug review","authors":"Vivek Srigadha, K. Prabhash, V. Noronha, A. Joshi, V. Patil, N. Menon, A. Singh, M. Shah","doi":"10.4103/crst.crst_9_23","DOIUrl":"https://doi.org/10.4103/crst.crst_9_23","url":null,"abstract":"Cabozantinib is a tyrosine kinase inhibitor that has been approved as therapy for several solid tumors, including metastatic renal cell carcinoma, hepatocellular carcinoma, and differentiated thyroid cancer. To prepare this review, we comprehensively searched various websites, including the United States Food and Drug Administration, the European Medicine Agency Drug Manual, PubMed, Science Direct, and UpToDate using the search terms, “cabozantinib,” “renal cell carcinoma,” “hepatocellular carcinoma,” “differentiated thyroid cancer,” and “medullary thyroid cancer.” We shortlisted all the full-text articles published between 2011 and 2022. Out of a total of 788 manuscripts identified, we included 52. This review of cabozantinib details the pharmacodynamics, pharmacokinetics, clinical indications, adverse effects, safety, and the key research trials that investigated the use of cabozantinib. We have discussed the available clinical trial data and real-world outcomes, both with respect to the efficacy and safety of cabozantinib.","PeriodicalId":9427,"journal":{"name":"Cancer Research, Statistics, and Treatment","volume":"20 1","pages":"74 - 87"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80428320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}